Surgery Partners (SGRY) has drawn fresh attention after its latest quarterly earnings, which combined revenue growth with continued net losses, while management reaffirmed full year guidance and emphasized a tighter focus on higher acuity procedures.

At a share price of $15.19, Surgery Partners has seen its short term share price return pick up over the past quarter, although the 1 year total shareholder return remains significantly weaker, which points to recovering but still fragile momentum after the latest earnings and M&A commentary.

If you are looking beyond Surgery Partners for ideas in healthcare related growth themes, this is a useful moment to check out 44 healthcare AI stocks

For Surgery Partners, the share price rebound sits against a longer stretch of weaker returns and ongoing losses. Does it make more sense to step in at today’s level, or to wait for a clearer margin of safety as valuation markers line up next?

Most Popular Narrative: 15.4% Undervalued

Compared with the current $15.19 share price, the most followed Surgery Partners narrative points to a fair value around $17.95, built on a detailed long term earnings and margin roadmap.

The accelerated migration of high-acuity surgical procedures (particularly orthopedics and joint replacements) from hospitals to outpatient settings is strengthening, with Surgery Partners demonstrating outperformance through investments in robotics and facility capabilities, positioning the company to capitalize on expanding case volumes and higher-revenue procedures directly supporting long-term revenue and EBITDA growth.

Want to see what sits behind that growth story? The narrative leans on steady revenue gains, firmer margins, and a richer case mix. Curious which financial levers matter most here? The full breakdown shows how those inputs tie back to the $17.95 fair value and a higher implied earnings multiple.

Result: Fair Value of $17.95 (UNDERVALUED)

However, the Surgery Partners narrative still faces real pressure from higher interest costs and slower than planned acquisitions, which could weigh on margins and cash generation.

Next Steps

If this mix of risks and optimism around Surgery Partners feels finely balanced, act now and review the 4 key rewards so you can weigh the potential upside for yourself.

Looking for more investment ideas beyond Surgery Partners?

If Surgery Partners has sharpened your focus on where capital goes next, do not stop here. Broader opportunity often sits just outside today’s watchlist.

• Target reliable compounding by reviewing companies in the 11 dividend fortresses that prioritize steady income alongside business resilience.
• Spot potential bargains early and see which stocks in the screener containing 18 high quality undiscovered gems are quietly building strong fundamentals before attention arrives.
• Lean toward resilience and sleep easier at night by scanning the 88 resilient stocks with low risk scores that screen well on quality and stability metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.